bacterico is a biotechnology startup developing personalized healthcare solutions based on an individual’s own gut microbiome. We isolate, select, and cultivate Bifidobacterium strains from stool samples and enhance them using proprietary culture methods to create personalized probiotic supplements optimized for each person’s gut environment. We also provide evidence-based programs tailored to key life moments, including Mama Flora, which supports maternal and infant health through prenatal gut microbiome care, and Preflora, a personalized nutrition and gut-health program designed specifically for individuals who are actively trying to conceive. Through science-driven, individualized interventions, bacterico aims to bring safe and effective microbiome-based solutions to everyday health.
[画像1: https://prtimes.jp/i/111676/2/resize/d111676-2-06f70f0da77fcc8956b1-0.png ] 株式会社bacterico(バクテリコ)は、一人ひとりの腸内フローラのデータに基づいて、自分に合った栄養指導などが専門家か...
[画像1: https://prtimes.jp/i/111676/1/resize/d111676-1-60da72fa9b6a1052da72-0.png ] 「mamaflora」とは、赤ちゃんが生まれる前から健やかな成長を支援することを目指し、一人ひとり異なる腸内細菌データに...

Solaris Bio revolutionizes regenerative medicine by integrating proprietary Animal-Origin-Free (AOF) formulation designs with advanced cell protection expertise. Centered on our "Organic Solvent-Free Cryopreservation Solution," which boasts the highest safety standards, we offer comprehensive cell manufacturing solutions, including world-class growth media. Leveraging innovative R&D and quality verified by the Certificate of Material Eligibility, we simultaneously enhance cell product efficacy and reduce costs, powerfully accelerating the social implementation of next-generation healthcare.

Our mission is to safeguard the health of people worldwide. We are an Osaka University-spun-off healthcare startup in the healthcare/preventive medicine field, developing and providing the “Blood Vessel Beauty” scope—which observes capillary blood flow from the fingertip without blood sampling—along with the capillary image analysis software ‘CAS’ and the cloud-based evaluation system “CAS-Rating.” We research the relationship between capillary data and health/disease risks, aiming to implement new health indicators and preventive medical services in society.

A startup using regenerative medicine technologies to produce and supply homogeneous, high-precision blood cells at scale. It streamlines infectious disease research and the evaluation of pharmaceuticals and functional materials for efficacy and safety, while also providing research cells, testing cells, and diagnostic kits.

A startup originating from the University of Tokyo and the University of Tsukuba, possessing proprietary technology for selectively amplifying hematopoietic stem cells in vitro. It aims to realize next-generation regenerative medicine through cell and gene therapies for blood disorders and genetic diseases, as well as vascular regeneration technology.